Canada secures new pandemic preparedness contract with CSL Seqirus for adjuvanted cell-based influenza vaccines.
This contract solidifies CSL Seqirus's role in national biosecurity for Canada, ensuring access to advanced influenza vaccines during a pandemic. It demonstrates the company's capability to secure large-scale government contracts and highlights the strategic importance of its cell-based vaccine technology for public health preparedness.
This agreement directly enhances Canada's national biosecurity and public health infrastructure by securing a supply of advanced influenza vaccines for pandemic response, reinforcing CSL Seqirus's position in the Canadian market.
Enhances Canada's pandemic response capabilities.
CSL Seqirus strengthens its government partnership portfolio.
Canada secures new pandemic preparedness contract with CSL Seqirus.
Contract covers adjuvanted cell-based influenza vaccines.
Enhances Canada's pandemic response capabilities.
Canada has entered into a new pandemic preparedness contract with CSL Seqirus, a global leader in influenza vaccines. Under the agreement, CSL Seqirus will supply adjuvanted cell-based vaccines to support Canada in the event of an influenza pandemic declared by the World Health Organization (WHO). This contract enhances Canada's biosecurity and response capabilities.
CSL announces expansion of Illinois plasma therapy manufacturing facility
Mar 12, 2026CSL Seqirus Signs Long-Term Agreement with The Pan-American Health Organization (PAHO) to Advance Regional Influenza Protection in the Region of the Americas
Mar 12, 2026Lilly and CSL Partner on Clazakizumab Antibody Development
Sign in to save notes on signals.
Sign In